Date: 2017-10-25
Type of information: Collaboration agreement
Compound: 3D bioprinting technology for advanced skin care applications
Company: Poietis (France) BASF (Germany)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism: bioprinting
Disease:
Details:
- • On July 10, 2015, BASF and Poietis have signed an agreement on research and development in cosmetics. Based on the combined expertise of both companies in tissue engineering and bioprinting, the agreement aims to apply the bioprinting technology of Poietis to improve BASF’s skin equivalent model MimeskinTM. The terms and conditions of this agreement were not disclosed.
- The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows for a precise positioning of the skin cells in three-dimensional structures. Through this, cells are cultivated within BASF’s skin model Mimeskin™, which is the closest equivalent to the original physiological tissue of human skin.
- Poietis’ bioprinting technology refines BASF’s skin model MimeskinTM due to its advanced printing resolution. The laser-assisted bioprinting technology will be used in a first step to allow for automated reproduction of MimeskinTM, followed by more advanced models containing additional cell types.
Financial terms:
Latest news:
- • On October 25, 2017, BASF and Poietis announced today the signature of a framework agreement on further development and services in the field of 3D bioprinting technology. The main goal is to further improve the 3D laser-assisted bioprinted skin models that have been co-developed since 2015 to evaluate cosmetic ingredients for skin care applications. The 3D laser-assisted bioprinting technology now allows to produce fully printed skin equivalents in only two weeks to further study active ingredients effectiveness. In a first step the new technology has been used to allow an automated reproduction of BASF’s skin model Mimeskin™, which is one of the closest equivalents to the original physiological tissue of human skin. In a second step, BASF and Poietis want to jointly improve the skin models by increasing structure complexity and adding new cell types.
Is general: Yes
